These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 30925939)

  • 1. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of Epstein-Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases.
    Qu H; Huang Y; Zhao S; Zhou Y; Lv W
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):9-18. PubMed ID: 31659449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
    Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
    Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
    Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.